US Stock Insider Trading | Insight Molecular disclosed one insider trading transaction on February 12

2026-03-07 00:21:41

On February 12, 2026, Insight Molecular (IMDX) disclosed an insider trading transaction. Shareholder BROADWOOD PARTNERS, L.P., holding more than 10% of shares, purchased 521,700 shares on February 10, 2026.

【Recent Insider Trading】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 12, 2026	Shareholder (>10%)	BROADWOOD PARTNERS, L.P.	February 10, 2026	Buy	521,700	5.75	3,000,000
February 11, 2025	Shareholder (>10%)	PATRICK W. SMITH	February 7, 2025	Buy	1,463,400	2.05	3,000,000
February 11, 2025	Executive	Andrea S. James	February 7, 2025	Buy	97,600	2.05	200,000
February 10, 2025	Shareholder (>10%)	BROADWOOD PARTNERS, L.P.	February 6, 2025	Buy	5,165,700	2.05	10,589,700
February 4, 2025	Shareholder (>10%)	PATRICK W. SMITH	February 4, 2025	Buy	25	2.02	50.50
January 31, 2025	Shareholder (>10%)	PATRICK W. SMITH	January 31, 2025	Buy	890	2.01	1,788.90
January 30, 2025	Shareholder (>10%)	PATRICK W. SMITH	January 30, 2025	Buy	4,198	2.01	8,437.98
January 14, 2025	Shareholder (>10%)	PATRICK W. SMITH	January 14, 2025	Buy	10,300	2.15	21,000
January 14, 2025	Shareholder (>10%)	PATRICK W. SMITH	January 14, 2025	Buy	5,769	2.08	12,000
December 26, 2024	Shareholder (>10%)	PATRICK W. SMITH	December 26, 2024	Buy	90,200	2.13	192,200

【Company Information】

Insight Molecular Diagnostics Inc. was incorporated in California in 2009 and is a majority-owned subsidiary of Bio Time. The company is a precision diagnostics firm focused on developing and commercializing three proprietary tests: VitaGraft, a blood-based organ transplant monitoring test; DetermaIO, a gene expression test that assesses tumor microenvironment to predict response to immunotherapy; and DetermaCNI, a blood-based monitoring tool for tracking treatment efficacy in cancer patients. The company is continuing development of DetermaIO, a promising test supported by data indicating its potential to identify patients likely to respond to checkpoint inhibitor drugs. These new drugs modulate immune responses and have shown activity across various solid tumor types, including non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.